The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 352-355 , August 2010

Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens

Received 29 May 2009 ,Revised 19 October 2009 ,Accepted 14 November 2009.

References 

  1. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63discussion 63-5
  2. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–3013
  3. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol. 2006;1:591–601Review
  4. Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60:259–263
  5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  6. d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, et al. Chemotherapy resistance and oncogene expression in non–small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:352–363
  7. d'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. Ann Thorac Surg. 2006;81:440–446discussion 446-7
  8. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002;87:8–16
  9. Mehta RS, Bornstein R, Yu IR, Parker RJ, McLaren CE, Nguyen KP, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat. 2001;66:225–237
  10. Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker R, Fruehauf JP, et al. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol. 2002;58:115–123
  11. Lyons JM, Abergel J, Thomson JL, Anthony CT, Wang YZ, Anthony LB, et al. In vitro chemoresistance testing in well-differentiated carcinoid tumors. Ann Surg Oncol. 2009;16:649–655Epub 2009 Jan 8
  12. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay–guided chemotherapy. Am J Obstet Gynecol. 2003;189:1301–1307
  13. Exiquon diagnostics. http://www.exiqon.com/dxps/Documents/edr_4_pager.pdf_Last entered 2009 Oct 17.
  14. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  15. Schinköthe T, Haeger S, Gabri MR. Practical guidelines for diagnostic use of in vitro chemosensitivity tests. Anticancer Res. 2007;27:1365–1367
  16. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22:3631–3638
  17. Cortazar P, Gazdar AF, Woods E, Russell E, Steinberg SM, Williams J, et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res. 1997;3:741–747
  18. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Nat Cancer Inst. 1990;82:582–588
  19. Fruehauf JP, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol. 2005;23:3641–3642
  20. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther. 2006;5:438–449
  21. McAlpine JN, Eisenkop SM, Spirtos NM. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol. 2008;110:360–364

 Disclosures: None.

PII: S0022-5223(10)00333-8

doi: 10.1016/j.jtcvs.2009.11.072

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 352-355 , August 2010

Article Tools

* Image Usage & Resolution